HSP60 as a drug target

Current Pharmaceutical Design

Volumn 19, Issue 3, 2013, Pages 441-451

  Nakamura, Hiroyuki ^a   Minegishi, Hidemitsu ^a  

^a GAKUSHUIN UNIVERSITY   (Japan)

Author keywords

Apoptosis; Biomarker; Carcinogenesis; HSP60; Inhibitor; Molecular chaperone; Proinflammatory response

Indexed keywords

15 DEOXYSPERGUALIN; 4 HYDROXYNONENAL; AMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBORANYLPHENOXYACETANILIDE; CHAPERONE; CHAPERONIN 60; CLUSTERIN; CYCLOSPORIN A; EARLY PREGNANCY FACTOR; EC 3016; EPOLACTAENE; MIZORIBINE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; RAPAMYCIN; TACROLIMUS; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL SURVIVAL; DRUG TARGETING; HEPATITIS B VIRUS; HUMAN; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRACELLULAR SIGNALING; KIDNEY GRAFT REJECTION; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS;

EID: 84876744831     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804143626     Document Type: Review

References (171)

1. Thirumalai D, Lorimer GH. Chaperonin-mediated protein folding. Annu Rev Biophys Biomol Struct 2001; 30: 245-69.
2. Ritossa F. A new puffing pattern induced by temperature shock and DNP in drosophila. Experientia 1962; 18: 571-3.
3. Tissiéres A, Mitchell HK, Tracy UM. Protein synthesis in salivary glands of Drosophila melanogaster: Relation to chromosome puffs. J Mol Biol 1974; 84: 389-98.
4. Schlesinger MJ. Heat shock proteins. J Biol Chem 1990; 265: 12111-4.
5. Bukau B, Horwich AL. The Hsp70 and Hsp60 chaperone machines. Cell 1998; 92: 351-66.
6. Eng C, Kiuru M, Fernandez MJ, Aaltonen LA. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nat Rev Cancer 2003; 3: 193-202.
7. Hohfeld J CD, Patterson C. From the cradle to the grave: Molecular chaperones that may choose between folding and degradation. EMBO Rep 2001; 2: 885-90.
8. Khalil AA, Kabapy NF, Deraz SF, Smith C. Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets? Biochem Biophys Acta 2011; 1816: 89-104.
9. Barazi HO, Zhou L, Templeton NS, Krutzsch HC, Roberts DD. Identification of heat shock protein 60 as a molecular mediator of α3β1 Integrin Activation. Cancer Res 2002; 62: 1541-8.
10. John Ellis R. Molecular chaperones: Pathways and networks. Curr Biol 1999; 9: R137-R9.
11. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. Journal of the National Cancer Institute 2000; 92: 1564-72.
12. Macario A. Heat-shock proteins and molecular chaperones: implications for pathogenesis, diagnostics, and therapeutics. Int J Clin Lab Res 1995; 25: 59-70.
13. Calderwood SK, Theriault JR, Gong J. Message in a bottle: Role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol 2005; 35: 2518-27.
14. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chap 2005; 10: 86-103.
15. Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006; 31: 164-72.
16. Banerji U, Walton M, Raynaud F, et al. Pharmacokineticpharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005; 11: 7023-32.
17. Jindal S, Dudani AK, Singh B, Harley CB, Gupta RS. Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen. Mol Cell Biol 1989; 9: 2279-83.
18. Hansen JJ, Bross P, Westergaard M, et al. Genomic structure of the human mitochondrial chaperonin genes: HSP60 and HSP are localised head to head on chromosome 2 separated by a bidirectional promoter. Human Genetics 2003; 112: 71-7.
19. Soltys BJ, Gupta RS. Mitochondrial-matrix proteins at unexpected locations: are they exported? Trends Biochem Sci 1999; 24: 174-7.
20. Deocaris CC, Kaul SC, Wadhwa R. On the brotherhood of the mitochondrial chaperones mortalin and heat shock protein 60. Cell Stress Chaperones 2006; 11: 116-28.
21. Czarnecka AM, Campanella C, Zummo G, Cappello F. Heat shock protein 10 and signal transduction: a "capsula eburnea" of carcinogenesis? Cell Stress Chaperones 2006; 11: 287-94.
22. Sigal L, Williams S, Soltys B, Gupta R. H9724, a monoclonal antibody to borrelia burgdorferi's flagellin, binds to heat shock protein 60 (hsp60) within live neuroblastoma cells: a potential role for hsp60 in peptide hormone signaling and in an autoimmune pathogenesis of the neuropathy of lyme disease. Cell Mol Neurobiol 2001; 21: 477-95.
23. Venner TJ, Singh B, Gupta RS. Nucleotide sequences and novel structural features of human and Chinese hamster hsp60 (chaperonin) gene families. DNA Cell Biol 1990; 9: 545-52.
24. Cheng MY, Hartl FU, Martin J, et al. Mitochondrial heat-shock protein hsp60 is essential for assembly of proteins imported into yeast mitochondria. Nature 1989; 337: 620-5.
25. Fayet O, Ziegelhoffer T, Georgopoulos C. The groES and groEL heat shock gene products of Escherichia coli are essential for bacterial growth at all temperatures. J Bacteriol 1989; 171: 1379-85.
26. Horwich AL, Low KB, Fenton WA, Hirshfield IN, Furtak K. Folding in vivo of bacterial cytoplasmic proteins: role of GroEL. Cell 1993; 74: 909-17.
27. Xu Z, Horwich AL, Sigler PB. The crystal structure of the asymmetric GroEL-GroES-(ADP)7 chaperonin complex. Nature 1997; 388: 741-50.
28. Rye HS, Burston SG, Fenton WA, et al. Distinct actions of cis and trans ATP within the double ring of the chaperonin GroEL. Nature 1997; 388: 792-8.
29. Nielsen KL, Cowan NJ. A single ring is sufficient for productive chaperonin-mediated folding in vivo. Mol Cell 1998; 2: 93-9.
30. Levy-Rimler G, Viitanen P, Weiss C, et al. The effect of nucleotides and mitochondrial chaperonin 10 on the structure and chaperone activity of mitochondrial chaperonin 60. Eur J Biochem 2001; 268: 3465-72.
31. Viitanen PV, Lorimer G, Bergmeier W, Weiss C, Kessel M, Goloubinoff. Purification of mammalian mitochondrial chaperonin 60 through in vitro reconstitution of active oligomers. Methods Enzymol 1998; 290: 203-17.
32. Chandrasekaran S, Guo N-h, Rodrigues RG Kaiser J, Roberts DD. Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by α3β1 integrin and regulated by insulin-like growth factor-1 and CD98. J Biol Chem 1999; 274: 11408-16.
33. Grundtman C, Kreutmayer SB, Almanzar G Wick MC, Wick G. Heat shock protein 60 and immune inflammatory responses in atherosclerosis. Arter Thromb Vascul Biol 2011; 31: 960-8.
34. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999; 103: 571-7.
35. Chen W, Syldath U, Bellmann K, Burkart V, Kolb H. Human 60-kDa heat-shock protein: a danger signal to the innate immune system. J Immunol 1999; 162: 3212-9.
36. Bethke K, Staib F, Distler M, et al. Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J Immunol 2002; 169: 6141-8.
37. Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 2000; 164: 13-7.
38. Vabulas RM, Ahmad-Nejad P, da Costa C, et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276: 31332-9.
39. Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558-61.
40. Feige U, Cohen IR. The 65-kDa heat-shock protein in the pathogenesis, prevention and therapy of autoimmune arthritis and diabetes mellitus in rats and mice. Springer Semin Immunopathol 1991; 13: 99-113.
41. Kamphuis S, Kuis W, de Jager W, et al. Tolerogenic immune responses to novel T-cell epitopes from heat-shock protein 60 in juvenile idiopathic arthritis. Lancet 2005; 366: 50-6.
42. Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun 1999; 12: 121-9.
43. Habich C, Baumgart K, Kolb H, Burkart V. The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins. J Immunol 2002; 168: 569-76.
44. Habich C, Kempe K, Gomez FJ, et al. Heat shock protein 60: identification of specific epitopes for binding to primary macrophages. FEBS Lett 2006; 580: 115-20.
45. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature 1985; 317: 489-95.
46. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.
47. Kondo Y, Kobayashi K, Ueno Y, et al. Mechanism of T cell hyporesponsiveness to HBcAg is associated with regulatory T cells in chronic hepatitis B. World J Gastroenterol 2006; 12: 4310-7.
48. Kondo Y, Ueno Y, Kobayashi K, et al. Hepatitis B virus replication could enhance regulatory T cell activity by producing soluble heat shock protein 60 from hepatocytes. J Infect Dis 2010; 202: 202-13.
49. Shannan B, Seifert M, Leskov K, et al. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ 2006; 13: 12-9.
50. Chaiwatanasirikul KA, Sala A. The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60. Cell Death Differ 2011; 2: e219.
51. Dunn S, Vohra RS, Murphy JE, Homer-vanniasinkam S, Walker JH, Ponnambalam S. The lectin-like oxidized low-densitylipoprotein receptor: a pro-inflammatory factor in vascular disease. Biochem J 2008; 409: 349-55.
52. Xie J, Zhu H, Guo L, et al. Lectin-like oxidized low-density lipoprotein receptor-1 delivers heat shock protein 60-fused antigen into the MHC class I presentation pathway. J Immunol 2010; 185: 2306-13.
53. Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347-54.
54. Thompson C. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
55. Samali A, Cai J, Zhivotovsky B, Jones DP, Orrenius S. Presence of a pre-apoptotic complex of pro-caspase-3, Hsp60 and Hsp10 in the mitochondrial fraction of Jurkat cells. EMBO J 1999; 18: 2040-8.
56. Campanella C, Bucchieri F, Ardizzone NM, et al. Upon oxidative stress, the antiapoptotic Hsp60/procaspase-3 complex persists in mucoepidermoid carcinoma cells. Eur J Histochem 2008; 52: 221-8.
57. Kirchhoff SR, Gupta S, Knowlton AA. Cytosolic heat shock protein 60, apoptosis, and myocardial injury. Circulation 2002; 105: 2899-904.
58. Chandra D, Choy G, Tang DG. Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release. J Biol Chem 2007; 282: 31289-301.
59. Zahn R, Spitzfaden C, Ottiger M, Wuthrich K, Pluckthun A. Destabilization of the complete protein secondary structure on binding to the chaperone GroEL. Nature 1994; 368: 261-5.
60. Zahn R, Perrett S, Fersht AR. Conformational states bound by the molecular chaperones GroEL and SecB: a hidden unfolding (annealing) activity. J Mol Biol 1996; 261: 43-61.
61. Zahn R, Perrett S, Stenberg G, Fersht AR. Catalysis of amide proton exchange by the molecular chaperones GroEL and SecB. Science 1996; 271: 642-5.
62. Itzhaki LS, Otzen DE, Fersht AR. Nature and consequences of GroEL-protein interactions. Biochemistry 1995; 34: 14581-7.
63. Persson M, Hammarström P, Lindgren M, Jonsson B-H, Svensson M, Carlsson U. EPR mapping of interactions between spin-labeled variants of human carbonic anhydrase II and GroEL: evidence for increased flexibility of the hydrophobic core by the interaction. Biochemistry 1998; 38: 432-41.
64. Todd MJ, Lorimer GH, Thirumalai D. Chaperonin-facilitated protein folding: optimization of rate and yield by an iterative annealing mechanism. Proc Natl Acad Sci USA 1996; 93: 4030-5.
65. Shtilerman M, Lorimer GH, Walter Englander S. Chaperonin function: folding by forced unfolding. Science 1999; 284: 822-5.
66. Hammarström P, Persson M, Owenius R, Lindgren M, Carlsson U. Protein substrate binding induces conformational changes in the chaperonin GroEL. J Biol Chem 2000; 275: 22832-8.
67. Wadhwa R, Takano S, Kaur K, et al. Identification and characterization of molecular interactions between mortalin/mtHsp70 and HSP60. Biochem J 2005; 391: 185-90.
68. Xanthoudakis S, Roy S, Rasper D, et al. Hsp60 accelerates the maturation of pro-caspase-3 by upstream activator proteases during apoptosis. EMBO J 1999; 18: 2049-56.
69. Cappello F, Conway de Macario E, Marasà L, Zummo G, Macario AJL. Hsp60 expression, new locations, functions, and perspectives for cancer diagnosis and therapy. Cancer Biol Ther 2008; 7: 801-9.
70. Bajramovic JJ GS, Bsibsi M, Boot M, Hassankhan R, Verhulst KC, van Noort JM. The stress kit: a new method based on competitive reverse transcriptase-polymerase chain reaction to quantify the expression of human alphaB-crystallin, Hsp27 and Hsp60. Cell Stress Chap 2000; 5: 30-5.
71. Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 2007; 98: 201-13.
72. Wehner PS, Nielsen B, Hokland M. Expression levels of hsc70 and hsp60 are developmentally regulated during B-cell maturation and not associated to childhood c-ALL at presentation or relapse. Eur J Haematol 2003; 71: 100-8.
73. Thomas X, Campos L, Mounier C, et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 2005; 29: 1049-58.
74. Chant ID, Rose PE, Morris AG. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br J Haematol 1995; 90: 163-8.
75. Hsu PL, Hsu SM. Abundance of heat shock proteins (hsp89, hsp60, and hsp27) in malignant cells of Hodgkin's disease. Cancer Res 1998; 58: 5507-13.
76. Kumamoto H, Suzuki T, Ooya K. Immunohistochemical analysis of inducible nitric oxide synthase (iNOS) and heat shock proteins (HSPs) in ameloblastomas. J Oral Pathol Med 2002; 31: 605-11.
77. Suzuki T, Kumamoto H, Ooya K, Motegi K. Expression of inducible nitric oxide synthase and heat shock proteins in periapical inflammatory lesions. J Oral Pathol Med 2002; 31: 488-93.
78. Fan G-K, Chen J, Ping F, Geng Y. Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissues. Oral Oncol 2006; 42: 147-53.
79. Li DQ, Wang L, Fei F, et al. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatographyion trap-mass spectrometry. Proteomics 2006; 6: 3352-68.
80. Sebastiani V, Botti C, Di Tondo U, et al. Tissue microarray analysis of FAS, Bcl-2, Bcl-x, ER, PgR, Hsp60, p53 and Her2-neu in breast carcinoma. Anticancer Res 2006; 26: 2983-7.
81. Carta F, Demuro PP, Zanini C, et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res 2005; 15: 235-44.
82. Uozaki H, Ishida T, Kakiuchi C, et al. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Practice 2000; 196: 665-73.
83. Trieb K, Gerth R, Windhager R, et al. serum antibodies against the heat shock protein 60 are elevated in patients with osteosarcoma. Immunobiol 2000; 201: 368-76.
84. Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S. Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy. Human Pathol 1998; 29: 1050-5.
85. Moon A, Bacchini P, Bertoni F, et al. Expression of heat shock proteins in osteosarcomas. Pathol J RCPA 42: 421-5 10.3109/00313025.2010.493866.
86. Merendino AM, Bucchieri F, Campanella C, et al. Hsp60 is actively secreted by human tumor cells. PLoS ONE 2010; 5: e9247.
87. Horvath I, Multhoff G, Sonnleitner A, Vigh L. Membraneassociated stress proteins: more than simply chaperones. Biochim Biophys Acta 2008; 1778: 1653-64.
88. de Gassart A, Géminard C, Février B, Raposo G, Vidal M. Lipid raft-associated protein sorting in exosomes. Blood 2003; 102: 4336-44.
89. Pfister G, Stroh CM, Perschinka H, et al. Detection of HSP60 on the membrane surface of stressed human endothelial cells by atomic force and confocal microscopy. J Cell Sci 2005; 118: 1587-94.
90. Thomas X, Campos L, Mounier C, et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res 2005; 29: 1049-58.
91. Chant ID, Rose PE, Morris AG. Analysis of heat-shock protein expression in myeloid leukaemia cells by flow cytometry. Br J Haematol 1995; 90: 163-8.
92. Hsu PL, Hsu SM. Abundance of heat shock proteins (hsp89, hsp60, and hsp27) in malignant cells of Hodgkin's disease. Cancer Res 1998; 58: 5507-13.
93. Chaiyarit P, Kafrawy AH, Miles DA, Zunt SL, Van Dis ML, Gregory RL. Oral lichen planus: an immunohistochemical study of heat shock proteins (HSPs) and cytokeratins (CKs) and a unifying hypothesis of pathogenesis. J Oral Pathol Med 1999; 28: 210-5.
94. Kawahara Y, Yokota K, Mizuno M, et al. Antibodies to human gastric epithelial cells and heat shock protein 60 in Helicobacter pylori positive mucosa associated lymphoid tissue lymphoma. Gut 1999; 45: 20-3.
95. Kawahara Y, Yokota K, Mizuno M, et al. Antibodies to human gastric epithelial cells and heat shock protein 60 in Helicobacter pylori positive mucosa associated lymphoid tissue lymphoma. Gut 1999; 45: 20-3.
96. Yamasaki R, Yokota K, Okada H, et al. Immune response in Helicobacter pylori-induced low-grade gastric-mucosa-associated lymphoid tissue (MALT) lymphoma. J Med Microbiol 2004; 53: 21-9.
97. Takenaka R, Yokota K, Mizuno M, et al. Serum antibodies to Helicobacter pylori and its heat-shock protein 60 correlate with the response of gastric mucosa-associated lymphoid tissue lymphoma to eradication of H. pylori. Helicobacter 2004; 9: 194-200.
98. Cappello F, Bellafiore M, Palma A, et al. 60KDa chaperonin (HSP60) is over-expressed during colorectal carcinogenesis. Eur J Histochem 2003; 47: 105-10.
99. Cappello F, David S, Rappa F, et al. The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer 2005; 5: 139.
100. Mori D, Nakafusa Y, Miyazaki K, Tokunaga O. Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays. Pathol Res Pract 2005; 201: 777-89.
101. Kuramitsu Y, Nakamura K. Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma. Expert Rev Proteomics 2005; 2: 589-601.
102. Cappello F, Rappa F, David S, Anzalone R, Zummo G. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis. Anticancer Res 2003; 23: 1325-31.
103. Johansson B, Pourian MR, Chuan YC, et al. Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heatshock protein 60 as a marker for prostate malignancy. Prostate 2006; 66: 1235-44.
104. Castle PE, Ashfaq R, Ansari F, Muller CY. Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. Cancer Lett 2005; 229: 245-52.
105. Cappello F, Bellafiore M, Palma A, et al. Expression of 60-kD heat shock protein increases during carcinogenesis in the uterine exocervix. Pathobiol 2002; 70: 83-8.
106. Tang D, Khaleque MA, Jones EL, et al. Expression of heat shock proteins and heat shock protein messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones 2005; 10: 46-58.
107. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000; 60: 7099-105.
108. Kimura E, Enns RE, Thiebaut F, Howell SB. Regulation of HSP60 mRNA expression in a human ovarian carcinoma cell line. Cancer Chemother Pharmacol 1993; 32: 279-85.
109. Bini L, Magi B, Marzocchi B, et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 1997; 18: 2832-41.
110. Pignatelli D, Ferreira J, Soares P, Costa MJ, Magalhaes MC. Immunohistochemical study of heat shock proteins 27, 60 and 70 in the normal human adrenal and in adrenal tumors with suppressed ACTH production. Microsc Res Tech 2003; 61: 315-23.
111. Trieb K, Gerth R, Windhager R, et al. Serum antibodies against the heat shock protein 60 are elevated in patients with osteosarcoma. Immunobiol 2000; 201: 368-76.
112. Uozaki H, Ishida T, Kakiuchi C, et al. Expression of heat shock proteins in osteosarcoma and its relationship to prognosis. Pathol Res Pract 2000; 196: 665-73.
113. Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci 2007; 98: 201-13.
114. Cappello F, Di Stefano A, D'Anna SE, Donner CF, Zummo G. Immunopositivity of heat shock protein 60 as a biomarker of bronchial carcinogenesis. Lancet Oncol 2005; 6: 816.
115. Cappello F, Di Stefano A, David S, et al. Hsp60 and Hsp10 downregulation predicts bronchial epithelial carcinogenesis in smokers with chronic obstructive pulmonary disease. Cancer 2006; 107: 2417-24.
116. Ito T, Kawabe R, Kurasono Y, et al. Expression of heat shock proteins in squamous cell carcinoma of the tongue: an immunohistochemical study. J Oral Pathol Med 1998; 27: 18-22.
117. Lebret T, Watson RW, Molinie V, et al. Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer 2003; 98: 970-7.
118. Cappello F, David S, Ardizzone N, et al. Expression of heat shock proteins HSP10, HSP27, HSP60, HSP70, and HSP90 in urothelial carcinoma of urinary bladder. J Cancer Mol 2006; 2: 73-7.
119. Kamishima T, Fukuda T, Usuda H, Takato H, Iwamoto H, Kaneko H. Carcinosarcoma of the urinary bladder: expression of epithelial markers and different expression of heat shock proteins between epithelial and sarcomatous elements. Pathol Int 1997; 47: 166-73.
120. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discovery Today 2008; 13: 38-43.
121. Chiosis G, Kang Y, Sun W. Discovery and development of purinescaffold Hsp90 inhibitors. Exp Opin Drug Discov 2008; 3: 99-114.
122. McDonald E, Jones K, Brough PA, Drysdale MJ, Workman P. Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr Top Med Chem 2006; 6: 1193-203.
123. Porter JR, Fritz CC, Depew KM. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. Curr Opin Chem Biol 2010; 14: 412-20.
124. Neckers L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr Top Med Chem 2006; 6: 1163-71.
125. Brodsky JL, Chiosis G. Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Curr Top Med Chem 2006; 6: 1215-25.
126. Williamson DS, Borgognoni J, Clay A, et al. Novel Adenosinederived inhibitors of 70 kDa heat shock protein, discovered through structure-based design. J Med Chem 2009; 52: 1510-3.
127. Leu JIJ, Pimkina J, Frank A, Murphy ME, George DL. A small molecule inhibitor of inducible heat shock protein 70. Mol Cell 2009; 36: 15-27.
128. Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K. Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiot (Tokyo) 1974; 27: 775-82.
129. Fukui M, Inaba M, Tsukagoshi S, Sakurai Y. New antitumor imidazole derivative, 5-carbamoyl-1H-imidazol-4-yl piperonylate, as an inhibitor of purine synthesis and its activation by adenine phosphoribosyltransferase. Cancer Res 1982; 42: 1098-102.
130. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996; 155: 1831-40.
131. Kamata K, Okubo M, Ishigamori E, et al. Immunosuppressive effect of bredinin on cell-mediated and humoral immune reactions in experimental animals. Transplant 1983; 35: 144-9.
132. Ichikawa Y, Ihara H, Takahara S, et al. The immunosuppressive mode of action of mizoribine. Transplant 1984; 38: 262-7.
133. Shiokawa Y, Honma M, Shichikawa K, et al. Clinical effectiveness of mizoribine on rheumatoid arthritis-A double-blind compara tive study using lobenzarit disodiurn as a standard drug-Ensho 1991; 11: 375-96.
134. Galat A. Peptidylproline cis-trans-isomerases: immunophilins. Eur J Biochem 1993; 216: 689-707.
135. van Roon JA, van Eden W, van Roy JL, Lafeber FJ, Bijlsma JW. Stimulation of suppressive T cell responses by human but not bacterial 60-kD heat-shock protein in synovial fluid of patients with rheumatoid arthritis. J Clin Invest 1997; 100: 459-63.
136. Itoh H, Komatsuda A, Wakui H, Miura AB, Tashima Y. Mammalian HSP60 is a major target for an immunosuppressant mizoribine. J Biol Chem 1999; 274: 35147-51.
137. Chapman E, Farr GW, Furtak K, Horwich AL. A small molecule inhibitor selective for a variant ATP-binding site of the chaperonin GroEL. Bioorg Med Chem Lett 2009; 19: 811-3.
138. Kakeya H, Takahashi I, Okada G, Isono K, Osada H. Epolactaene, a novel neuritogenic compound in human neuroblastoma cells, produced by a marine fungus. J Antibiot (Tokyo) 1995; 48: 733-5.
139. Kakeya H, Onozawa C, Sato M, Arai K, Osada H. Neuritogenic effect of epolactaene derivatives on human neuroblastoma cells which lack high-affinity nerve growth factor receptors. J Med Chem 1997; 40: 391-4.
140. Mizushina Y, Kobayashi S, Kuramochi K, Nagata S, Sugawara F, Sakaguchi K. Epolactaene, a novel neuritogenic compound in human neuroblastoma cells, selectively inhibits the activities of mammalian DNA polymerases and human DNA topoisomerase II. Biochem Biophys Res Commun 2000; 273: 784-8.
141. Nakai J, Kawada K, Nagata S, et al. A novel lipid compound, epolactaene, induces apoptosis: its action is modulated by its side chain structure. Biochim Biophys Acta 2002; 1581: 1-10.
142. Nagumo Y, Kakeya H, Yamaguchi J, et al. Structure-activity relationships of epolactaene derivatives: structural requirements for inhibition of Hsp60 chaperone activity. Bioorg Med Chem Lett 2004; 14: 4425-9.
143. Nagumo Y, Kakeya H, Shoji M, Hayashi Y, Dohmae N, Osada H. Epolactaene binds human Hsp60 Cys442 resulting in the inhibition of chaperone activity. Biochem J 2005; 387: 835-40.
144. Marnett LJ, Riggins JN, West JD. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Invest 2003; 111: 583-93.
145. Schneider C, Tallman KA, Porter NA, Brash AR. Two distinct pathways of formation of 4-hydroxynonenal. Mechanisms of nonenzymatic transformation of the 9-and 13-hydroperoxides of linoleic acid to 4-hydroxyalkenals. J Biol Chem 2001; 276: 20831-8.
146. West JD, Marnett LJ. Endogenous reactive intermediates as modulators of cell signaling and cell death. Chem Res Toxicol 2006; 19: 173-94.
147. Uchida K, Toyokuni S, Nishikawa K, et al. Michael addition-type 4-hydroxy-2-nonenal adducts in modified low-density lipoproteins: markers for atherosclerosis. Biochemistry 1994; 33: 12487-94.
148. Grune T, Siems WG, Schonheit K, Blasig IE. Release of 4-hydroxynonenal, an aldehydic mediator of inflammation, during postischaemic reperfusion of the myocardium. Int J Tissue React 1993; 15: 145-50.
149. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997; 68: 2092-7.
150. Selley ML. (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic Biol Med 1998; 25: 169-74.
151. Montine TJ, Huang DY, Valentine WM, et al. Crosslinking of apolipoprotein E by products of lipid peroxidation. J Neuropathol Exp Neurol 1996; 55: 202-10.
152. Vila A, Tallman KA, Jacobs AT, Liebler DC, Porter NA, Marnett LJ. Identification of protein targets of 4-hydroxynonenal using click chemistry for ex vivo biotinylation of azido and alkynyl derivatives. Chem Res Toxicol 2008; 21: 432-44.
153. Oksala NKJ, Laaksonen DE, Lappalainen J, et al. Heat shock protein 60 response to exercise in diabetes: Effects of α-lipoic acid supplementation. J Diabetes Complications 2006; 20: 257-61.
154. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
155. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-4.
156. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-74.
157. Sun L, Liang C, Shirazian S, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46: 1116-9.
158. Atkins M, Jones CA, Kirkpatrick P. Sunitinib maleate. Nat Rev Drug Discov 2006; 5: 279-80.
159. Semenza GL. Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. J Clin Invest 2001; 108: 39-40.
160. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-32.
161. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
162. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275: 25733-41.
163. Berra E, Richard DE, Gothié E, Pouysségur J. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1[alpha] degradation. FEBS Letters 2001; 491: 85-90.
164. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468-72.
165. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292: 464-8.
166. Dawn B, Bolli R. HO-1 induction by HIF-1: a new mechanism for delayed cardioprotection? Am J Physiol 2005; 289: H522-4.
167. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA 1998; 95: 14389-94.
168. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
169. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Medicine 2003; 9: 677-84.
170. Shimizu K, Maruyama M, Yasui Y, Minegishi H, Ban HS, Nakamura H. Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1[alpha] inhibitors. Bioorg Med Chem Lett 2010; 20: 1453-6.
171. Lee K, Lee JH, Boovanahalli SK, et al. (Aryloxyacetylamino) benzoic Acid Analogues: A New Class of Hypoxia-Inducible Factor-1 Inhibitors. J Med Chem 2007; 50: 1675-84.